EP3805271A1 - Method for preparing sugammadex sodium salt - Google Patents
Method for preparing sugammadex sodium salt Download PDFInfo
- Publication number
- EP3805271A1 EP3805271A1 EP19812545.2A EP19812545A EP3805271A1 EP 3805271 A1 EP3805271 A1 EP 3805271A1 EP 19812545 A EP19812545 A EP 19812545A EP 3805271 A1 EP3805271 A1 EP 3805271A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- sugammadex sodium
- sodium
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KMGKABOMYQLLDJ-VKHHSAQNSA-F sugammadex sodium Chemical class [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O([C@@H]([C@@H]([C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O3)O[C@@H]2CSCCC([O-])=O)O)[C@H](CSCCC([O-])=O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]3[C@@H](CSCCC([O-])=O)O1 KMGKABOMYQLLDJ-VKHHSAQNSA-F 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 10
- 229940041622 sugammadex sodium Drugs 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 49
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 229910001385 heavy metal Inorganic materials 0.000 claims description 9
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 claims description 7
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
- 150000008046 alkali metal hydrides Chemical class 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- -1 phosphorus halide Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 0 CCC(*)CC(NC(C(C)(C)C)=*)=O Chemical compound CCC(*)CC(NC(C(C)(C)C)=*)=O 0.000 description 2
- 206010029315 Neuromuscular blockade Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920002370 Sugammadex Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940041644 bridion Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 description 1
- 229960000491 rocuronium Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
- 229960003819 vecuronium Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Definitions
- the present invention relates to a process for preparing sugammadex sodium. More particularly, the present invention relates to an efficient process for preparing sugammadex sodium with high purity.
- 6-Mercaptocyclodextrin derivatives are useful for the reversal of drug-induced neuromuscular blockade.
- U.S. Patent No. 6,670,340 discloses that sugammadex sodium represented by the following formula (1) (6-per-deoxy-6-per-(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt) is useful for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
- the sugammadex sodium of formula (1) is an active pharmaceutical ingredient (API) of Bridion which is an antagonist of muscle relaxants.
- U.S. Patent No. 6,670,340 discloses a process for preparing sugammadex sodium by reacting 6-per-deoxy-6-per-iodo-gamma-cyclodextrin with 3-mercaptopropionic acid using an alkali metal hydride under the anhydrous DMF condition, as shown in the following reaction scheme 1.
- U.S. Patent No. 9,120,876 discloses a process for preparing sugammadex sodium by synthesizing 6-per-deoxy-6-per-halo-gamma-cyclodextrin using phosphorus halide and then reacting the 6-per-deoxy-6-per-halo-gamma-cyclodextrin with 3-mercaptopropionic acid using an alkali metal hydride as a base, as shown in the following reaction scheme 2.
- One embodiment of the present invention relates to a process for preparing sugammadex sodium of the following formula (1), which comprises the steps of:
- X is F, Cl, Br or I. Particularly, X is Br.
- the preparation process according to one embodiment of the present invention may further comprise the step of drying the compound of formula (2) to a moisture content of 2 wt% or less before the step (i).
- the preparation process according to one embodiment of the present invention may further comprise the step of subjecting the compound of formula (4) obtained by the step (i) to recrystallization using dimethylformamide (DMF) and acetonitrile (ACN) to remove triphenylphosphine oxide.
- DMF dimethylformamide
- ACN acetonitrile
- the preparation process according to one embodiment of the present invention may further comprise the step of purifying the sugammadex sodium of formula (1) obtained by the step (ii) with aminopropyl-functionalized silica to remove a heavy metal.
- reaction scheme 3 and reaction scheme 4 The process depicted in the following reaction scheme 3 and reaction scheme 4 represents merely a typical example, and various changes may be made to reagents and reaction conditions without limitation.
- Step 1 Synthesis of Compound of Formula (4)
- the compound of formula (4) can be prepared by reacting the compound of formula (2) with the compound of formula (3) in the presence of triphenylphosphine.
- the compound of formula (2) may be dried to have a moisture content of 2 wt% or less, for example, about 1 wt% to 2 wt%, particularly 2 wt% before it is used for the synthesis of the compound of formula (4).
- the equivalent ratio of the compound of formula (2) to the compound of formula (3) may be 1 : 0.4 to 0.6, particularly 1:0.5.
- reaction solvent acetone, ACN, DMF, dimethyl sulfoxide (DMSO), etc.
- DMF dimethyl sulfoxide
- the reaction temperature is suitably about 50 to 90 °C, and the reaction time is preferably about 5 to 15 hours.
- the compound of formula (4) obtained by the step (i) may be purified before it is used for the synthesis of the sugammadex sodium of formula (1).
- the compound of formula (4) can be purified by recrystallization using dimethylformamide (DMF) and acetonitrile (ACN) to remove triphenylphosphine oxide.
- DMF dimethylformamide
- ACN acetonitrile
- the volume ratio of the dimethylformamide (DMF) to the acetonitrile (ACN) may be 1:1 to 1:5, preferably 1:2.
- Step 2 Preparation of Sugammadex Sodium of Formula (1)
- the sugammadex sodium of formula (1) can be prepared by reacting the compound of formula (4) with 3-mercaptopropionic acid in the presence of a sodium salt.
- sodium salt sodium hydroxide, sodium methoxide, etc. may be used.
- reaction solvent acetone, ACN, DMF, DMSO, etc. may be used. Particularly, DMF is preferred.
- the reaction temperature is suitably about 50 to 90 °C, and the reaction time is preferably about 10 to 20 hours.
- the sugammadex sodium of formula (1) obtained by the step (ii) can be purified with aminopropyl-functionalized silica to remove a heavy metal.
- the sugammadex sodium of formula (1) can be contaminated with a heavy metal since the sulfur (S) atoms in the molecule may coordinate to the heavy metal.
- the heavy metal such as Fe, Cu, etc. can be removed from the sugammadex sodium of formula (1) using the aminopropyl-functionalized silica.
- aminopropyl-functionalized silica commercially available products may be used.
- QuadraSil AP from Johnson Matthey may be used.
- the aminopropyl-functionalized silica may be used in an amount of 2 to 5 wt%, particularly 3 wt%, based on 100 wt% of the sugammadex sodium of formula (1).
- One embodiment of the present invention relates to a process for preparing a compound of the following formula (4), which comprises the step of:
- the process for preparing the compound of formula (4) includes the same step (i) as in the above process for preparing sugammadex sodium, and thus a detailed description thereof will be omitted to avoid repetition.
- sugammadex sodium having high purity can be efficiently prepared.
- the phosphorus halide which is expensive and difficult to handle is not used in the synthesis of 6-per-deoxy-6-per-halo-gamma-cyclodextrin which is an intermediate, and triphenylphosphine oxide which is produced as a by-product can be efficiently removed.
- sugammadex sodium can be easily prepared with high purity.
- the compound of formula (4) (6.7 g) was added to DMF (22.4 mL), and stirred for 15 minutes, followed by filtration to remove impurities.
- the filtrate was warmed to 45 °C, and then ACN (45.2 mL) was added dropwise thereto for 1 hour. Then, the temperature was gradually lowered to room temperature, followed by stirring for 1 hour to give a solid precipitate.
- the filtration was carried out with washing with ACN (12.3 mL) for 30 minutes, and the filtered residue was vacuum-dried at 60 °C for 12 hours to obtain a compound of formula (4) (6 g, 77%).
- the purity of the obtained compound of formula (4) was 99.82%, and it was confirmed that triphenylphosphine oxide was completely removed.
- the dried sugammadex sodium of formula (1) (2.53 g) was completely dissolved in distilled water (5.06 mL) and methanol (5.06 mL), and then an aminopropyl-functionalized silica (Johnson Matthey, QuadraSil AP) (0.0759 g) was added thereto, followed by stirring for 1 hour. After filtration, the filtrate was warmed to 50 ⁇ 60 °C, and then methanol (22.5 mL) was added thereto at the same temperature. The resulting solution was cooled to room temperature and stirred for 2 hours, followed by filtration. The filtered residue was vacuum-dried at 60 °C for 12 hours to give sugammadex sodium of formula (1) (3.0 g, 83 %). The purity of the sugammadex sodium of formula (1) was 97.69%.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Sustainable Development (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
- The present invention relates to a process for preparing sugammadex sodium. More particularly, the present invention relates to an efficient process for preparing sugammadex sodium with high purity.
- 6-Mercaptocyclodextrin derivatives are useful for the reversal of drug-induced neuromuscular blockade. Particularly,
U.S. Patent No. 6,670,340 discloses that sugammadex sodium represented by the following formula (1) (6-per-deoxy-6-per-(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt) is useful for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. - The sugammadex sodium of formula (1) is an active pharmaceutical ingredient (API) of Bridion which is an antagonist of muscle relaxants.
-
U.S. Patent No. 6,670,340 discloses a process for preparing sugammadex sodium by reacting 6-per-deoxy-6-per-iodo-gamma-cyclodextrin with 3-mercaptopropionic acid using an alkali metal hydride under the anhydrous DMF condition, as shown in the following reaction scheme 1. - However, in the first reaction step of the preparation process of sugammadex sodium, triphenylphosphine oxide which is too difficult to remove is produced in the synthesis of 6-per-deoxy-6-per-iodo-gamma-cyclodextrin. Further, the alkali metal hydride used for the synthesis of the sugammadex sodium in the second reaction step is difficult to handle since it is sensitive to moisture. Also, the sugammadex sodium prepared by the preparation process has a problem of low purity.
- Further,
U.S. Patent No. 9,120,876 - However, in the above preparation process of sugammadex sodium, phosphorus halide which is quite difficult to handle is used in the synthesis of the 6-per-deoxy-6-per-halo-gamma-cyclodextrin which is an intermediate, and triphenylphosphine oxide which is difficult to remove is produced. Also, the process has a problem of using the alkali metal hydride which is sensitive to moisture in the preparation of sugammadex sodium, and using column chromatographic membrane dialysis in the purification process, which makes it difficult to be applied to mass production in terms of costs.
- It is an object of the present invention to provide a cost-effective and efficient process for preparing sugammadex sodium with high purity.
- One embodiment of the present invention relates to a process for preparing sugammadex sodium of the following formula (1), which comprises the steps of:
- (i) reacting a compound of the following formula (2) with a compound of the following formula (3) in the presence of triphenylphosphine to obtain a compound of the following formula (4); and
- (ii) reacting the compound of the following formula (4) with 3-mercaptopropionic acid in the presence of a sodium salt:
- In one embodiment of the present invention, X is F, Cl, Br or I. Particularly, X is Br.
- The preparation process according to one embodiment of the present invention may further comprise the step of drying the compound of formula (2) to a moisture content of 2 wt% or less before the step (i).
- The preparation process according to one embodiment of the present invention may further comprise the step of subjecting the compound of formula (4) obtained by the step (i) to recrystallization using dimethylformamide (DMF) and acetonitrile (ACN) to remove triphenylphosphine oxide.
- The preparation process according to one embodiment of the present invention may further comprise the step of purifying the sugammadex sodium of formula (1) obtained by the step (ii) with aminopropyl-functionalized silica to remove a heavy metal.
- Hereinafter, the preparation process of the present invention is described in more detail referring to the following reaction scheme 3 and reaction scheme 4. The process depicted in the following reaction scheme 3 and reaction scheme 4 represents merely a typical example, and various changes may be made to reagents and reaction conditions without limitation.
- The compound of formula (4) can be prepared by reacting the compound of formula (2) with the compound of formula (3) in the presence of triphenylphosphine.
- The compound of formula (2) may be dried to have a moisture content of 2 wt% or less, for example, about 1 wt% to 2 wt%, particularly 2 wt% before it is used for the synthesis of the compound of formula (4).
- The equivalent ratio of the compound of formula (2) to the compound of formula (3) may be 1 : 0.4 to 0.6, particularly 1:0.5.
- As the reaction solvent, acetone, ACN, DMF, dimethyl sulfoxide (DMSO), etc. may be used. Particularly, DMF is preferred.
- The reaction temperature is suitably about 50 to 90 °C, and the reaction time is preferably about 5 to 15 hours.
- The compound of formula (4) obtained by the step (i) may be purified before it is used for the synthesis of the sugammadex sodium of formula (1).
- Specifically, the compound of formula (4) can be purified by recrystallization using dimethylformamide (DMF) and acetonitrile (ACN) to remove triphenylphosphine oxide.
- The volume ratio of the dimethylformamide (DMF) to the acetonitrile (ACN) may be 1:1 to 1:5, preferably 1:2.
- The sugammadex sodium of formula (1) can be prepared by reacting the compound of formula (4) with 3-mercaptopropionic acid in the presence of a sodium salt.
- As the sodium salt, sodium hydroxide, sodium methoxide, etc. may be used.
- As the reaction solvent, acetone, ACN, DMF, DMSO, etc. may be used. Particularly, DMF is preferred.
- The reaction temperature is suitably about 50 to 90 °C, and the reaction time is preferably about 10 to 20 hours.
- The sugammadex sodium of formula (1) obtained by the step (ii) can be purified with aminopropyl-functionalized silica to remove a heavy metal.
- The sugammadex sodium of formula (1) can be contaminated with a heavy metal since the sulfur (S) atoms in the molecule may coordinate to the heavy metal. In accordance with the present invention, the heavy metal such as Fe, Cu, etc. can be removed from the sugammadex sodium of formula (1) using the aminopropyl-functionalized silica.
- As the aminopropyl-functionalized silica, commercially available products may be used. For example, QuadraSil AP from Johnson Matthey may be used.
- The aminopropyl-functionalized silica may be used in an amount of 2 to 5 wt%, particularly 3 wt%, based on 100 wt% of the sugammadex sodium of formula (1).
- One embodiment of the present invention relates to a process for preparing a compound of the following formula (4), which comprises the step of:
- (i) reacting a compound of the following formula (2) with a compound of the following formula (3) in the presence of triphenylphosphine:
X is halogen. - The process for preparing the compound of formula (4) includes the same step (i) as in the above process for preparing sugammadex sodium, and thus a detailed description thereof will be omitted to avoid repetition.
- In accordance with the preparation process of the present invention, sugammadex sodium having high purity can be efficiently prepared. Particularly, in accordance with the preparation process of the present invention, the phosphorus halide which is expensive and difficult to handle is not used in the synthesis of 6-per-deoxy-6-per-halo-gamma-cyclodextrin which is an intermediate, and triphenylphosphine oxide which is produced as a by-product can be efficiently removed. Thus, sugammadex sodium can be easily prepared with high purity.
- Hereinafter, the present invention will be described in more detail by the following examples. It will be obvious to those skilled in the art that these examples are merely described for illustration of the present invention and the scope of the present invention is not limited thereto.
- The compound of formula (3) (10.7 g) wherein X is Br was added to DMF (35.6 mL), followed by stirring. Triphenylphosphine (19.5 g) was dividedly added in 5 times thereto while maintaining the temperature of 10 °C or less, and the temperature was gradually raised to room temperature. A solution in which the compound of formula (2) (5.6 g) having moisture content adjusted to 2 wt% was diluted with DMF (35.6 mL) was added thereto, followed by stirring for 2 hours. The resulting solution was heated to 85 °C and stirred for 12 hours. The reaction progress was confirmed by HPLC. The resulting solution was cooled to room temperature, and methanol (14.7 mL) was added thereto, followed by stirring for 30 minutes. The temperature of the resulting solution was lowered to -10 °C, and then 25% sodium methoxide-methanol solution (10.47 mL) was added thereto, followed by stirring for 30 minutes. Distilled water (58.5 mL) was added dropwise thereto for 1 hour, and then stirred for 1 hour, followed by filtration. The filtered residue was washed with distilled water (15 mL) and filtered for 30 minutes. The filtered residue was added to methanol (93 mL) and stirred for 1 hour, followed by filtration with washing with methanol (24 mL). Vacuum drying was performed at 60 °C for 12 hours to give a compound of formula (4) (6.7 g).
- The compound of formula (4) (6.7 g) was added to DMF (22.4 mL), and stirred for 15 minutes, followed by filtration to remove impurities. The filtrate was warmed to 45 °C, and then ACN (45.2 mL) was added dropwise thereto for 1 hour. Then, the temperature was gradually lowered to room temperature, followed by stirring for 1 hour to give a solid precipitate. The filtration was carried out with washing with ACN (12.3 mL) for 30 minutes, and the filtered residue was vacuum-dried at 60 °C for 12 hours to obtain a compound of formula (4) (6 g, 77%). The purity of the obtained compound of formula (4) was 99.82%, and it was confirmed that triphenylphosphine oxide was completely removed.
- 1H NMR (300 MHz, DMSO): δ 6.01-5.97 (2H, m), 5.02 (1H, d, J = 3.6 Hz), 3.98 (1H, d, J = 9.6 Hz), 3.82 (1H, t, J = 9.0 Hz), 3.71-3.59 (2H, m), 3.44-3.36 (2H, m).
- 25% Sodium methoxide-methanol solution (11.43 mL) was added to DMF (24 mL), followed by stirring. The resulting solution was cooled to 0 °C, and 3-mercaptopropionic acid (2.18 mL) was added dropwise thereto while maintaining the temperature of 10 °C or less. The resulting solution was gradually warmed to room temperature and stirred for 1 hour. The solution in which the compound of formula (4) (3 g) was dissolved in DMF (9 mL) was added thereto, and then the temperature was raised to 85 °C, followed by stirring for 18 hours. The reaction progress was confirmed by HPLC. The resulting solution was cooled to room temperature, and then distilled water (36 mL) was added thereto, followed by warming to 50~60 °C. Then, methanol (50 mL) was added thereto at the same temperature. The resulting solution was cooled to room temperature and stirred for 2 hours, followed by filtration. The filtered residue was vacuum-dried at 60 °C for 12 hours to give sugammadex sodium of formula (1) (3.02 g, 83.5%).
- The dried sugammadex sodium of formula (1) (2.53 g) was completely dissolved in distilled water (5.06 mL) and methanol (5.06 mL), and then an aminopropyl-functionalized silica (Johnson Matthey, QuadraSil AP) (0.0759 g) was added thereto, followed by stirring for 1 hour. After filtration, the filtrate was warmed to 50~60 °C, and then methanol (22.5 mL) was added thereto at the same temperature. The resulting solution was cooled to room temperature and stirred for 2 hours, followed by filtration. The filtered residue was vacuum-dried at 60 °C for 12 hours to give sugammadex sodium of formula (1) (3.0 g, 83 %). The purity of the sugammadex sodium of formula (1) was 97.69%.
- 1H NMR (300 MHz, D2O): δ 5.13 (1H, d, J = 3.9 Hz), 4.03-3.86 (1H, m), 3.90 (1H, t, J = 9.6 Hz), 3.63-3.56 (2H, m), 3.10-3.06 (1H, m), 2.94 (1H, dd, J = 13.8, 6.3 Hz), 2.81 (2H, t, J = 7.2 Hz), 2.46-2.41 (2H, m).
- Compounds of formula (4) were synthesized using compounds of formula (2) having various moisture contents as shown in Table 1 below, and were analyzed by HPLC. The results are shown in Table 1 below.
[Table 1] Moisture Content Area Value of Compound of Formula (4) Area Value of Related Substance (Retention Time: 18.0 minutes) 1.697 wt% 99.54% 0.13% 2 wt% 99.64% 0.15% 3 wt% 0.65% 99.34% 5 wt% 0.59% 99.27% 11 wt% 0.11% 99.88% - From the results of Table 1 above, it can be confirmed that as the moisture content of the compound of formula (2) increased, the area value of the compound of formula (4) decreased and the area value of the related substance increased. In case of adjusting the moisture content of the compound of formula (2) down to 2 wt%, the area value of the compound of formula (4) was 99 wt% or more, and the area value of the related substance was 0.2% or less. Therefore, it can be confirmed that the yield of the compound of formula (4) can be highly increased by lowering the moisture content of the compound of formula (2) to 2 wt% or less.
- Amounts of heavy metal components were measured by Inductively Coupled Plasma Mass Spectrometer (ICP Mass), before and after the sugammadex sodium of formula (1) was purified with the aminopropyl-functionalized silica. The results are shown in Table 2 below.
[Table 2] As Cd Cr Cu Hg Mo Ni Pb Sn Fe Before Treatment N.D. N.D. N.D. 41.3 ppm N.D. N.D. N.D. N.D. N.D. 345 ppm After Treatment N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. - From the results of Table 2 above, it can be confirmed that the heavy metals were efficiently removed after the sugammadex sodium of formula (1) was purified with the aminopropyl-functionalized silica. Accordingly, it can be seen that the purification process using the aminopropyl-functionalized silica was effective in the reaction process.
X is halogen.
Claims (9)
- A process for preparing sugammadex sodium of the following formula (1), which comprises the steps of:(i) reacting a compound of the following formula (2) with a compound of the following formula (3) in the presence of triphenylphosphine to obtain a compound of the following formula (4); and(ii) reacting the compound of the following formula (4) with 3-mercaptopropionic acid in the presence of a sodium salt:wherein,
X is halogen. - The process according to claim 1, wherein X is Br.
- The process according to claim 1, wherein the sodium salt is sodium hydroxide or sodium methoxide.
- The process according to claim 1, further comprising the step of drying the compound of formula (2) to a moisture content of 2 wt% or less before the step (i).
- The process according to claim 1, further comprising the step of subjecting the compound of formula (4) obtained by the step (i) to recrystallization using dimethylformamide (DMF) and acetonitrile (ACN) to remove triphenylphosphine oxide.
- The process according to claim 5, wherein a volume ratio of the dimethylformamide (DMF) to the acetonitrile (ACN) is 1:1 to 1:5.
- The process according to claim 1, further comprising the step of purifying the sugammadex sodium of formula (1) obtained by the step (ii) with an aminopropyl-functionalized silica to remove a heavy metal.
- The process according to claim 7, wherein the aminopropyl-functionalized silica is used in an amount of 2 to 5 wt%, based on 100 wt% of the sugammadex sodium of formula (1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180060624A KR102054228B1 (en) | 2018-05-28 | 2018-05-28 | Process for Preparing Sugammadex Sodium |
PCT/KR2019/006143 WO2019231166A1 (en) | 2018-05-28 | 2019-05-22 | Method for preparing sugammadex sodium salt |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3805271A1 true EP3805271A1 (en) | 2021-04-14 |
EP3805271A4 EP3805271A4 (en) | 2022-03-09 |
Family
ID=68698291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19812545.2A Pending EP3805271A4 (en) | 2018-05-28 | 2019-05-22 | Method for preparing sugammadex sodium salt |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3805271A4 (en) |
JP (1) | JP7144873B2 (en) |
KR (1) | KR102054228B1 (en) |
WO (1) | WO2019231166A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111040050A (en) * | 2019-12-26 | 2020-04-21 | 徐州工业职业技术学院 | Method for purifying sugammadex sodium |
JP7512762B2 (en) | 2020-08-20 | 2024-07-09 | ニプロ株式会社 | Liquid preparations containing sugammadex |
CN113637097A (en) * | 2021-08-10 | 2021-11-12 | 北京恒创星远医药科技有限公司 | 6-full-deoxidation-6-full-iodo-gamma-cyclodextrin crystal and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI242015B (en) * | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
WO2012025937A1 (en) | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | Improved process for preparation of sugammadex |
US9879096B2 (en) * | 2013-02-14 | 2018-01-30 | Neuland Laboratories Limited | Process for preparation of sugammadex sodium |
CN105348412B (en) * | 2014-08-22 | 2018-06-05 | 江苏恩华药业股份有限公司 | A kind of purification process for the more glucose sodium that relaxes |
CN104628891B (en) * | 2015-01-20 | 2017-05-03 | 中国大冢制药有限公司 | Method for preparing 6-deoxy-6-haloalkyl cyclodextrin |
CN104844732B (en) * | 2015-03-27 | 2017-05-03 | 山东滨州智源生物科技有限公司 | Preparation method for sugammadex sodium |
JP6946275B2 (en) | 2015-05-29 | 2021-10-06 | ラクシュミ・プラサド・アラパルティLakshmi Prasad ALAPARTHI | Manufacturing method of Sugamadex and its intermediates |
US20180016359A1 (en) * | 2016-06-29 | 2018-01-18 | Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. | Sugammadex preparation and purification method |
-
2018
- 2018-05-28 KR KR1020180060624A patent/KR102054228B1/en active IP Right Grant
-
2019
- 2019-05-22 JP JP2020566774A patent/JP7144873B2/en active Active
- 2019-05-22 EP EP19812545.2A patent/EP3805271A4/en active Pending
- 2019-05-22 WO PCT/KR2019/006143 patent/WO2019231166A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3805271A4 (en) | 2022-03-09 |
WO2019231166A1 (en) | 2019-12-05 |
KR102054228B1 (en) | 2019-12-10 |
KR20190135312A (en) | 2019-12-06 |
JP2021524879A (en) | 2021-09-16 |
JP7144873B2 (en) | 2022-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100917698B1 (en) | Improved process for the preparation of letrozole | |
EP3805271A1 (en) | Method for preparing sugammadex sodium salt | |
EP3421504B1 (en) | Process for making sugammadex | |
EP2789610A1 (en) | Purification of Posaconazole Intermediates | |
EP4047047A1 (en) | Purification of sugammadex | |
JP5140583B2 (en) | Process for the preparation of 4β-amino-4'-demethyl-4-desoxypodophyllotoxin | |
KR102481697B1 (en) | Preparing method of ectoine and Ectoine prepared by the same method | |
WO2021190604A1 (en) | Preparation of cyclosporin derivatives | |
EP3088391B1 (en) | Method for producing benzyl ester 2-aminonicotinate derivative | |
EP0080819B1 (en) | 11-0-alkylerythromycin a derivatives | |
EP0026894B1 (en) | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | |
JP5065020B2 (en) | Process for producing levofloxacin or a hydrate thereof | |
JP2012020970A (en) | Method for producing {3-(1-diphenylmethylazetidin-3-yl)ester-5-isopropyl ester 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate} | |
KR20170060035A (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
DE69221006T2 (en) | Mitomycin derivatives | |
JP3884063B2 (en) | Cefcapene pivoxil methanesulfonate | |
KR100911720B1 (en) | A process for preparing crystal foam of sarpogrelate hcl | |
CN113045491B (en) | Preparation method of lenvatinib and intermediate | |
WO2001005750A1 (en) | p-TERPHENYL COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL SIDE CHAINS | |
WO2020129591A1 (en) | Production method for amide alcohol compound | |
KR20160065496A (en) | Recrystallization method for purification of phenoxy-2(1h)-pyrimidinone analogues | |
EP2938617B1 (en) | Process for preparing meropenem trihydrate | |
CN114195784A (en) | Pabociclib related substance, preparation method and application thereof | |
DE2306001C3 (en) | Pyrimidine derivatives, processes for their preparation and poultry feed compositions containing them | |
EP2154137A1 (en) | Crystalline form of moxifloxacin base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220204 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C08B 37/00 20060101ALI20220131BHEP Ipc: C08B 37/16 20060101AFI20220131BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |